Healthcare Policy

Healthcare Policy 13(2) November 2017 : 68-78.doi:10.12927/hcpol.2017.25321
Research Paper

Prior Authorization and Canadian Public Utilization of Direct-Acting OralĀ Anticoagulants

Lulu Gao, Mina Tadrous, Sandra Knowles, Muhammad Mamdani, J. Michael Paterson, David Juurlink and Tara Gomes

Abstract

Purpose: Provincial public drug formularies in Canada have different mechanisms for reimbursement of direct-acting oral anticoagulants (DOACs). We investigate how these differences influence DOAC utilization and expenditure across the country.

Methods: We conducted a population-based, cross-sectional study of all out-patient prescriptions for OACs dispensed to public beneficiaries between January 1, 2010, and June 30, 2015. We calculated quarterly rates of OAC use and expenditures stratified by OAC type and province.

Results: The greatest increase in quarterly rates of DOAC utilization occurred in provinces with more liberal mechanism of drug coverage: Ontario by 462%, Alberta by 425% and Quebec by 1,924%. This translated to increased expenditure on overall OAC by 270%, 204% and 390%, respectively. In contrast, provinces with more stringent mechanisms had low rates of DOAC utilization and expenditure.

Conclusions: DOAC utilization and expenditure is considerably different across Canada, associated with provincial difference in reimbursement mechanism.

 

Comments

Be the first to comment on this!

Related Articles

Note: Please enter a display name. Your email address will not be publically displayed